REFERENCES
- Eriksson S. Pulmonary emphysema and alpha1-antitrypsin deficiency. Acta Med Scand 1964; 175(2)197–205, [PUBMED], [INFOTRIEVE], [CSA]
- Eriksson S. Studies in alpha1-antitrypsin deficiency. Acta Med Scand (Suppl) 1965; 432: 1–85, [CSA]
- Morse J O. Alpha1-antitrypsin deficiency. NEJM 1978; 299: 1045–8, 1099-1105[PUBMED], [INFOTRIEVE], [CSA]
- Crystal R G. α 1-antitrypsin deficiency, emphysema, and liver disease. J Clin Invest 1990; 85: 1343–1352, [PUBMED], [INFOTRIEVE], [CSA]
- Stoller J K. Clinical features and natural history of severe α1-antitrypsin deficiency. Chest 1997; 111: 123S–128S, [PUBMED], [INFOTRIEVE], [CSA]
- World Health Organization. Alpha-1-antitrypsin deficiency. Report of WHO Meeting, World Health Organization, GenevaSwitzerland, March, 18–201996
- Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118(5)1480–1485, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gadek J E, Fells G A, Zimmerman R L, Rennard S I, Crystal R G. Antielastases of the human alveolar structures; implications for the protease-antiprotease theory of emphysema. J Clin Invest 1981; 68: 889–898, [PUBMED], [INFOTRIEVE], [CSA]
- Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha-1-antitrypsin deficiency-related pulmonary emphysema with human alpha-1-antitrypsin. Eur Resp J 1998; 11: 428–433, [CROSSREF], [CSA]
- Wewers M D, Casolaro M A, Sellers S E, Swayze S C, McPhaul K M, Wittes J T, Crystal R G. Replacement therapy for alpha1-antitrypsin deficiency associated with emphysema. NEJM 1987; 316: 1055–1062, [PUBMED], [INFOTRIEVE], [CSA]
- Alpha1-Antitrypsin Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Resp Crit Care Med 1998; 158: 49–59, [CSA]
- Seersholm N. Does alpha-1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha-1-antitrypsin deficiency?. Eur Resp J 1997; 10(10)2260–2263, [CROSSREF], [CSA]
- American Thoracic Society/European Respiratory Society Statement. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Resp Crit Care Med 2003; 168: 818–900, [CROSSREF], [CSA]
- Cowden D I, Fisher G E, Weeks R L. A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) products. Curr Med Res Opin 2005; 21(6)877–883, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Morikawa T, Yoshida M A. Useful testing strategy in phase iii trials: combined test of superiority and test of equivalence. J Biopharm Stat 1995; 5(3)297–306, [PUBMED], [INFOTRIEVE], [CSA]
- Dunnet C W, Gent M. An alternative to the use of two-sided tests in clinical trials. Stat Med 1996; 15: 1729–1738, [CROSSREF], [CSA]
- Stoller J K, Rouhani F, Brantly M, Shahi S, Dweik R A, Stocks J M, Clausen J, Campbell E, Norton F. Biochemical efficacy and safety of a new pooled human plasma α 1-antitrypsin, respitin. Chest 2002; 122: 66–74, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bernhardt D, Schäfer W, Mehdi S, Nowak T, Weimer T, Gröner A. Advances in Transfusion Safety. Paul-Ehrlich-Institute, LangenGermany June, 2001, 7–8
- Gröner A, Nowak T, Römisch J. Purity, activity and virus safety of a pasteurized antithrombin concentrate. Semin Thromb Hemost 2002; 28(Suppl. 1)79–85, [CSA]